Table 1.
GRADE evaluation of interventions for acute anterior uveitis
| Important outcomes | Disease severity, adverse effects | ||||||||
| Number of studies (participants) | Outcome | Comparison | Type of evidence | Quality | Consistency | Directness | Effect size | GRADE | Comment |
| What are the effects of anti-inflammatory eye drops on acute anterior uveitis? | |||||||||
| 1 (60) | Disease severity | Corticosteroid eye drops v placebo eye drops | 4 | –3 | 0 | 0 | 0 | Very low | Quality points deducted for sparse data, incomplete reporting of results, poor follow-up, and no intention-to-treat analysis |
| 4 in 2 reports (516) | Disease severity | Corticosteroid eye drops v each other | 4 | –2 | 0 | 0 | 0 | Low | Quality points deducted for no intention to treat analysis in 2 RCTs (people excluded from analysis) and only reporting results for subgroup of people enrolled in 1 RCT |
| 1 (64) | Disease severity | NSAID eye drops v placebo eye drops | 4 | –2 | 0 | –2 | 0 | Very low | Quality points deducted for sparse data and no intention-to-treat analysis. Directness points deducted for unclear outcome (clinical cure) and co-intervention (atropine) |
| 3 (173) | Disease severity | NSAID eye drops v corticosteroid eye drops | 4 | –2 | 0 | –2 | 0 | Very low | Quality points deducted for sparse data and no intention-to-treat analysis. Directness point deducted for unclear outcome (clinical cure) and co-intervention (atropine) |
Type of evidence: 4 = RCT. Consistency: similarity of results across studies Directness: generalisability of population or outcomes Effect size: based on relative risk or odds ratio